Antineoplastic chemotherapy induced QTc prolongation

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 93-96

  Bagnes, Claudia ^a   Panchuk, Patricia Natalia ^a   Recondo, Gonzalo ^b  

^a HOSPITAL DURAND   (Argentina)

^b CEMIC   (Argentina)

Author keywords

Antineoplastics; Chemotherapy; Cytostatic; HERG channel; QT interval prolongation; Torsades de pointes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FREE RADICAL; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IMATINIB; LAPATINIB; NILOTINIB; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; PAZOPANIB; POTASSIUM CHANNEL HERG; PRAVASTATIN; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL DEATH; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG TARGETING; ECG ABNORMALITY; HEART INFARCTION; HEART REPOLARIZATION; HUMAN; ISCHEMIA; KIDNEY CANCER; LUNG CANCER; ONCOGENE NEU; OXIDATIVE STRESS; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; TACHYCARDIA; UNSTABLE ANGINA PECTORIS; VASOSPASM;

ANIMALS; ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; NEOPLASMS; RISK FACTORS; TORSADES DE POINTES;

EID: 77950815765     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869111     Document Type: Review

References (38)

1. National Cancer Institute: Cancer therapy evaluation program, Common terminology for adverse events, version 3.0 DCTD, NCI, NIH, DHHS, 2006. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
2. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. J Am Med Assoc 2003; 289: 2120-2127
3. Sanguinetti MC, Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature 2006; 440 (7083): 463-469
4. Anderson ME, Al-Khatib SA, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002; 144: 769-781
5. Fingert H, Varterasian M. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 2006; 8(1): E89-94.
6. ICH. E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005a.
7. ICH. S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2005b.
8. Pudil R, Horacek JM, Horackova J, Jebavy L, Vojacek J. Anthracycline therapy can induce very early increase in QT dispersion and QTc prolongation. Leuk Res 2008; 32(6): 998-999
9. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100(15): 1058-1067
10. Schimmel KJM, Richel DJ, van den Brink RBA, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-191
11. Galetta F, Franzoni F, Cervetti G, et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005; 59(10): 541-544
12. Ewer MS. The anthracycline-Trastuzumab interaction: up-regulated binding may provide vital mechanistic insight. Eur J Cancer 2007; 43(14): 2024-2025
13. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029-1033
14. Becker K, Erckenbrecht JF, Haussinger D. Frieling. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 54: 475-484
15. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8(2): 191-202.
16. Cheng CF, Juan SH, Chen JJ, et al. Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis 2008; 13(7): 883-894
17. Gianni L, Vigan L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 2007; 15 (5): 1906-1915
18. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimization of treatment schedules for anthracyclines and paclitaxel in cancer patients. Clin Pharmacokinet 1999; 9: 135-211.
19. Salvatorelli E, Menna P, Gianni L, Minotti G. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 2007; 320(2): 790-800.
20. Strevel EL, Ing DJ, Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25: 3362-3371
21. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26(32): 5204-5212
22. Morabito A, Piccirillo MC, Falasconi F, et al. (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009; 14(4): 378-390
23. Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 2008; 106(1): 153-161
24. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009; 53: 2231-2247
25. Yavas O, Yazici M, Eren O, Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly 2007; 137(39-40): 556-558
26. Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J 2007; 13(2): 211-212
27. Genentech Inc. Bevacizumab Prescribing Information [online]. 2008. Available from: http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf.
28. Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008; 4(6): 1367-1370
29. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12(12): 3762-3773
30. Olsen E, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25(21): 3109-3115
31. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008; 26(2): 332-333
32. Pan J, Chen B, Su CH, et al. Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biol Ther 2008; 7(10): 1679-1684
33. Zhou J, Vos CC, Gjyrezi A, et al. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem 2009; 284 (15): 9648-9655
34. Yang CH, Kies MS, Glisson B. A phase II study on lonafarnib(SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma. J Clin Oncol 2005; 23: 16S (abstract 5565).
35. Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009 [Epub ahead of print].
36. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 2008; 87(11): 881-885
37. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 2009; 15(10): 3617-3623
38. Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol 2007; 47(9): 1138-1151